Cyclerion Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Cyclerion Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q2 2024.
Cyclerion Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$1.38M, a 25.8% increase year-over-year.
Cyclerion Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$10.8M, a 495% decline year-over-year.
Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$13M, a 30.1% increase from 2022.
Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.5M, a 66.4% increase from 2021.
Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$55.2M, a 32.1% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	-$10.8M	-$1.38M	+$481K	+25.8%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-07
Q1 2024	-$11.3M	-$1.62M	+$1.66M	+50.6%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$13M	-$1.8M	-$14.2M	-114%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-05
Q3 2023	$1.24M	-$6.02M	-$1.5M	-33.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-13
Q2 2023	$2.74M	-$1.87M	+$11.6M	+86.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-07
Q1 2023	-$8.83M	-$3.28M	+$9.71M	+74.8%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$18.5M	$12.4M	+$26.7M		Oct 1, 2022	Dec 31, 2022	10-K	2024-03-05
Q3 2022	-$45.3M	-$4.52M	+$6.77M	+60%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-13
Q2 2022	-$52M	-$13.4M	+$2.74M	+17%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-07-28
Q1 2022	-$54.8M	-$13M	+$411K	+3.07%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-12
Q4 2021	-$55.2M	-$14.3M	+$4.89M	+25.4%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-22
Q3 2021	-$60.1M	-$11.3M	+$10.5M	+48.2%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$70.6M	-$16.2M	+$3.5M	+17.8%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$74.1M	-$13.4M	+$7.19M	+34.9%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-04
Q4 2020	-$81.3M	-$19.2M	+$7.36M	+27.7%	Oct 1, 2020	Dec 31, 2020	10-K	2022-02-24
Q3 2020	-$88.6M	-$21.8M	+$6.24M	+22.3%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-09
Q2 2020	-$94.9M	-$19.7M	+$13.4M	+40.5%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-29
Q1 2020	-$108M	-$20.6M	+$16.8M	+44.9%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-30
Q4 2019	-$125M	-$26.6M	+$4.32M	+14%	Oct 1, 2019	Dec 31, 2019	10-K	2021-02-25
Q3 2019	-$129M	-$28M	+$1.27M	+4.34%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	-$131M	-$33.1M	-$3.27M	-11%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-03
Q1 2019	-$127M	-$37.4M	-$12.1M	-47.9%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-04
Q4 2018	-$115M	-$30.9M			Oct 1, 2018	Dec 31, 2018	10-K	2020-03-12
Q3 2018		-$29.3M			Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-12
Q2 2018		-$29.8M			Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-12
Q1 2018		-$25.3M			Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-13

* An asterisk sign (*) next to the value indicates that the value is likely invalid.